• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Lu]Lu-PSMA-617 合成过程中副产物的鉴定、表征和抑制。

Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [Lu]Lu-PSMA-617.

机构信息

Department of Nuclear Medicine, Saarland University-Medical Center, Kirrbergerstrasse, D-66421 Homburg, Germany.

Department of Nuclear Medicine, Medical Center-University of Freiburg, D-79106 Freiburg, Germany.

出版信息

J Med Chem. 2021 Apr 22;64(8):4960-4971. doi: 10.1021/acs.jmedchem.1c00045. Epub 2021 Apr 7.

DOI:10.1021/acs.jmedchem.1c00045
PMID:33826320
Abstract

In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report on the formation of radioactive impurities formed during the clinical production of Lu-labeled PSMA-617. We provide compelling evidence that these impurities are the result of a spontaneous, thermally mediated condensation reaction of the Glu-CO-Lys moiety resulting in the formation of three different five-membered ring systems. Density functional theory (DFT) calculations show that the condensation and cyclization of the Glu-CO-Lys moiety is thermodynamically spontaneous. In cell experiments, no affinity of these cyclized compounds toward PSMA was observed. HPLC analyses of urine samples from patient studies showed rapid renal excretion of these radioactive cyclized species. Radiolabeling conditions were identified that significantly reduced the formation of cyclized side products yielding Lu-labeled PSMA-617 in high radiochemical yield and purity in concordance with current good manufacturing practice (cGMP) requirements.

摘要

近年来,针对前列腺特异性膜抗原(PSMA)的放射性示踪剂在前列腺癌的管理中产生了巨大的影响。在这里,我们报告了在临床生产 Lu 标记的 PSMA-617 过程中形成的放射性杂质。我们提供了令人信服的证据,证明这些杂质是 Glu-CO-Lys 部分自发的、热介导的缩合反应的结果,导致形成了三种不同的五元环系统。密度泛函理论(DFT)计算表明,Glu-CO-Lys 部分的缩合和环化在热力学上是自发的。在细胞实验中,没有观察到这些环状化合物对 PSMA 的亲和力。来自患者研究的尿液样本的 HPLC 分析表明,这些放射性环状物质迅速经肾脏排泄。已经确定了放射性标记条件,可以显著减少环状副产物的形成,从而以高放射化学产率和纯度生成符合现行良好生产规范(cGMP)要求的 Lu 标记的 PSMA-617。

相似文献

1
Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [Lu]Lu-PSMA-617.[Lu]Lu-PSMA-617 合成过程中副产物的鉴定、表征和抑制。
J Med Chem. 2021 Apr 22;64(8):4960-4971. doi: 10.1021/acs.jmedchem.1c00045. Epub 2021 Apr 7.
2
Automated radiosynthesis of [ Ga]Ga-PSMA-11 and [ Lu]Lu-PSMA-617 on the iPHASE MultiSyn module for clinical applications.在 iPHASE MultiSyn 模块上自动化合成用于临床应用的[Ga]Ga-PSMA-11 和 [Lu]Lu-PSMA-617。
J Labelled Comp Radiopharm. 2021 Mar;64(3):140-146. doi: 10.1002/jlcr.3889. Epub 2020 Nov 2.
3
Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [Lu]Lu-PSMA-617 in Healthy Organs.发现谷氨酸羧肽酶 III 配体以竞争健康器官中 [Lu]Lu-PSMA-617 的摄取。
J Med Chem. 2024 May 23;67(10):8247-8260. doi: 10.1021/acs.jmedchem.4c00332. Epub 2024 May 8.
4
Enhancing Treatment Efficacy of Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.通过结合白蛋白结合基序来增强 Lu-PSMA-617 的治疗效果:临床前剂量学和内放射治疗研究。
Mol Pharm. 2018 Nov 5;15(11):5183-5191. doi: 10.1021/acs.molpharmaceut.8b00720. Epub 2018 Oct 5.
5
Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.使用(177)Lu标记的PSMA抑制剂进行前列腺癌靶向治疗中中等比活度(177)Lu的前景。
J Labelled Comp Radiopharm. 2016 Jul;59(9):364-71. doi: 10.1002/jlcr.3414. Epub 2016 Jun 6.
6
Multidose formulation of ready-to-use Lu-PSMA-617 in a centralized radiopharmacy set-up.在集中式放射性药物药房设置中使用即用型Lu-PSMA-617的多剂量制剂。
Appl Radiat Isot. 2018 Sep;139:91-97. doi: 10.1016/j.apradiso.2018.04.033. Epub 2018 Apr 26.
7
Quality Assurance Investigations and Impurity Characterization during Upscaling of [Lu]Lu-PSMA.在 Lu-PSMA 的放大过程中进行质量保证调查和杂质特征分析。
Molecules. 2023 Nov 21;28(23):7696. doi: 10.3390/molecules28237696.
8
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.一种定制的、带有优化连接基团的DOTA偶联PSMA抑制剂用于前列腺癌成像和内放射治疗的临床前评估
J Nucl Med. 2015 Jun;56(6):914-20. doi: 10.2967/jnumed.114.147413. Epub 2015 Apr 16.
9
Production and Quality Control of [Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials.[镥]Lu-PSMA-I&T 的生产和质量控制:临床试验用研究药物档案的开发。
Molecules. 2022 Jun 28;27(13):4143. doi: 10.3390/molecules27134143.
10
Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.(177)镥标记的PSMA-617的临床翻译:前列腺癌患者的初步经验。
Nucl Med Biol. 2016 May;43(5):296-302. doi: 10.1016/j.nucmedbio.2016.02.002. Epub 2016 Feb 15.

引用本文的文献

1
Multifactorial analysis of radiochemical purity in high-activity Lu-labeled theranostics: impact of precursor source, Lu form, and production parameters.高活性镥标记诊疗剂放射化学纯度的多因素分析:前体来源、镥形态及生产参数的影响
EJNMMI Radiopharm Chem. 2025 Jul 22;10(1):47. doi: 10.1186/s41181-025-00372-5.
2
A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents.一种用于临床级镥-177标记的诊疗剂放射性合成的可扩展方案。
Nat Protoc. 2025 May 27. doi: 10.1038/s41596-025-01176-2.
3
Reply to: Byproducts in the synthesis of [Ga]Ga-PSMA-11.
回复:[镓]镓-PSMA-11合成中的副产物
Nat Protoc. 2025 Apr 18. doi: 10.1038/s41596-025-01163-7.
4
Byproducts in the synthesis of [Ga]Ga-PSMA-11.[镓]镓-PSMA-11合成中的副产物。
Nat Protoc. 2025 Apr 18. doi: 10.1038/s41596-025-01164-6.
5
Improvement of End-of-Synthesis Radiochemical Purity of Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization.采用替代合成方法提高镥-多胺多羧基配体-前列腺特异性膜抗原配体合成终产物的放射化学纯度:转化率上升及副产物最小化
Pharmaceutics. 2024 Nov 30;16(12):1535. doi: 10.3390/pharmaceutics16121535.
6
Automated radiosynthesis and preclinical evaluation of two new PSMA-617 derivatives radiolabelled via [F]AlF method.通过[F]AlF方法对两种新的PSMA - 617衍生物进行放射性标记的自动化放射性合成及临床前评估。
EJNMMI Radiopharm Chem. 2024 Jun 21;9(1):50. doi: 10.1186/s41181-024-00280-0.
7
Quality Assurance Investigations and Impurity Characterization during Upscaling of [Lu]Lu-PSMA.在 Lu-PSMA 的放大过程中进行质量保证调查和杂质特征分析。
Molecules. 2023 Nov 21;28(23):7696. doi: 10.3390/molecules28237696.
8
Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer.镥-177标记的前列腺特异性膜抗原-617用于前列腺癌的分子成像和靶向放射性配体治疗
Adv Pharm Bull. 2023 Nov;13(4):701-711. doi: 10.34172/apb.2023.079. Epub 2023 Apr 29.
9
Synthesis, I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures.新型基于尿素的 PSMA 抑制剂的合成、I-放射性标记优化及初步临床前评价,其结构中含有三丁基锡基拟肽基团。
Int J Mol Sci. 2023 Jul 30;24(15):12206. doi: 10.3390/ijms241512206.
10
Radiolysis-Associated Decrease in Radiochemical Purity of Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process.辐射分解相关的镥放射性药物放射化学纯度降低及几种淬灭剂对此过程效果的比较。
Molecules. 2023 Feb 16;28(4):1884. doi: 10.3390/molecules28041884.